ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,099.96
      1.02%
      US Tech 100
      17,244.80
      1.57%
      Dow Jones
      38,239.66
      0.40%
      Brent Oil
      88.165
      0.00%
      Bitcoin
      63,580.75
      0.27%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Valneva SE (VLA)

      7. Valneva SE (VLA) News

      VLA

      Valneva (VLA)

      Valneva SE
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:VLA
      DateTimeSourceHeadlineSymbolCompany
      04/04/202412:00PMGlobeNewswire Inc.Déclaration d'actions et de droits de vote de la société Valneva SE - mars 2024EU:VLAValneva SE
      04/04/202412:00PMGlobeNewswire Inc.Declaration of voting rights - Valneva SE, March 2024EU:VLAValneva SE
      03/26/20242:00AMGlobeNewswire Inc.Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine CandidateEU:VLAValneva SE
      03/26/20242:00AMGlobeNewswire Inc.Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième génération contre le virus ZikaEU:VLAValneva SE
      03/26/20242:00AMGlobeNewswire Inc.Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine CandidateEU:VLAValneva SE
      03/25/20242:00AMGlobeNewswire Inc.Valneva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son rapport annuel américain « Form 20-F »EU:VLAValneva SE
      03/25/20242:00AMGlobeNewswire Inc.Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-FEU:VLAValneva SE
      03/25/20242:00AMGlobeNewswire Inc.Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-FEU:VLAValneva SE
      03/21/20242:00AMGlobeNewswire Inc.Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.EU:VLAValneva SE
      03/21/20242:00AMGlobeNewswire Inc.Valneva fera une présentation sur son vaccin contre le chikungunya, IXCHIQ®, et participera à plusieurs événements lors du 24ème World Vaccine Congress à Washington, D.C.EU:VLAValneva SE
      03/21/20242:00AMGlobeNewswire Inc.Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.EU:VLAValneva SE
      03/20/20242:00AMGlobeNewswire Inc.Valneva Reports Full Year 2023 Results and Provides Business Updates and OutlookEU:VLAValneva SE
      03/18/20242:00AMGlobeNewswire Inc.Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMedEU:VLAValneva SE
      03/18/20242:00AMGlobeNewswire Inc.Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMedEU:VLAValneva SE
      03/18/20242:00AMGlobeNewswire Inc.Valneva annonce un report de la date de début de remboursement du prêt contracté avec les sociétés Deerfield et OrbiMedEU:VLAValneva SE
      03/06/20242:30AMGlobeNewswire Inc.VALNEVA Declaration of shares and voting rights - February 29, 2024EU:VLAValneva SE
      03/06/20242:30AMGlobeNewswire Inc.Déclaration d’actions et de droits de vote de la société Valneva - 29 février 2024EU:VLAValneva SE
      03/04/20241:00AMGlobeNewswire Inc.Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor ConferencesEU:VLAValneva SE
      03/04/20241:00AMGlobeNewswire Inc.Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor ConferencesEU:VLAValneva SE
      03/04/20241:00AMGlobeNewswire Inc.Valneva fera une présentation lors des conférences investisseurs TD Cowen et Van Lanschot KempenEU:VLAValneva SE
      02/29/20241:00AMGlobeNewswire Inc.U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®EU:VLAValneva SE
      02/29/20241:00AMGlobeNewswire Inc.Le Comité consultatif sur la vaccination aux États-Unis (ACIP) recommande l’utilisation d’IXCHIQ®, le vaccin à injection unique contre le chikungunya de ValnevaEU:VLAValneva SE
      02/29/20241:00AMGlobeNewswire Inc.U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®EU:VLAValneva SE
      02/15/20241:00AMGlobeNewswire Inc.Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 GuidanceEU:VLAValneva SE
      02/15/20241:00AMGlobeNewswire Inc.Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 GuidanceEU:VLAValneva SE
      02/15/20241:00AMGlobeNewswire Inc.Valneva publie son chiffre d’affaires et sa trésorerie pour l’exercice 2023 et fournit des indications préliminaires pour l’exercice 2024EU:VLAValneva SE
      02/07/20242:30AMGlobeNewswire Inc.VALNEVA: Declaration of shares and voting rights - January 31, 2024EU:VLAValneva SE
      02/07/20242:30AMGlobeNewswire Inc.VALNEVA : Déclaration d’actions et de droits de vote - 31 janvier 2024EU:VLAValneva SE
      02/05/20241:00AMGlobeNewswire Inc.Valneva Announces Sale of Priority Review Voucher for $103 MillionEU:VLAValneva SE
      02/05/20241:00AMGlobeNewswire Inc.Valneva annonce la vente de son bon de revue prioritaire (PRV) pour 103 millions de dollarsEU:VLAValneva SE
       Showing the most relevant articles for your search:EU:VLA